February 11, 2026

min read

Feb 11, 2026

💬 Daily Observation

“The desire to act is often a desire to stop feeling uncertain.” — Annie Duke

A good investing system doesn’t remove uncertainty. It gives you a place to put your hands when uncertainty shows up — rebalance rules, contribution schedules, and a plan you don’t renegotiate on nervous days. Most costly mistakes aren’t bad math, they’re stress purchases.

🗞️ Today’s Stories That Matter (And Why)

1. 🧑‍💼 Jobs report beat expectations, but 2025 was revised sharply lower

The US added 130,000 jobs in January with unemployment at 4.3%. The bigger story: 2025 job growth was revised down to +181,000 from +584,000 — a major downgrade. Wages rose 0.4% m/m and 3.7% y/y.

Why it matters: Stronger-today data can delay rate cuts, but a weaker underlying trend can still pull investors toward bonds — exactly why balanced portfolios hold up better when the narrative flips mid-flight.

Assets in Focus: Fixed Income

2. 🧾 Congress reopened the door to votes challenging Trump-era tariffs

The House rejected a procedural effort that would have blocked votes challenging emergency tariffs, reopening a path for Congress to challenge the framework. Trade policy is back in play.

Why it matters: Tariffs can hit portfolios from two angles — stocks (profits/supply chains) and bonds (inflation expectations) — exactly the kind of cross-asset shock diversification is built for.

Assets in Focus: Equities

3. 📈 Stocks and yields moved in opposite directions after the jobs surprise

Markets had a classic “good news / bad news” reaction: the jobs beat supported growth but raised the chance the Fed stays patient. The 10-year yield rose to ~4.17% while the Dow fell ~190 points in choppy trading.

Why it matters: The rate story can overpower the earnings story without warning — portfolios with a single engine feel bumpier than investors expect.

Assets in Focus: Equities, Fixed Income

4. 🧬 FDA refused to file Moderna’s mRNA flu vaccine application

Moderna’s stock fell ~11% after the FDA issued a rare “refusal-to-file” letter for its mRNA flu vaccine, citing trial design issues (not safety or efficacy concerns).

Why it matters: Healthcare is often treated as “defensive,” but biotech can behave like high-volatility tech — making diversification within equities more important than people assume.

Assets in Focus: Equities

5. 🪙 Crypto-linked stocks slid as bitcoin stayed under pressure

Coinbase, Strategy, and Robinhood were among notable decliners. Bitcoin was around ~$67,000, down ~23% since January. When rates feel “higher for longer,” the most speculative assets feel it first.

Why it matters: Crypto is best understood as a volatility amplifier. A meaningful slice of your net worth in crypto can dominate your risk profile even when everything else is fine.

Assets in Focus: Alternatives

🌀 Diversification Score

Calculate my score

🤯 Alternative Investment Highlight: 🧾 Two 10-Cent Comics, One $13M Deal

A Superman #1 (1939) sold for $7M and a Batman #1 (1940) sold for $6M in a private sale. The Batman issue is famous for the first appearances of the Joker and Catwoman — the buyer didn’t just buy paper, they bought an origin story.

🧠 From the Education Center

Diversification: A Practical Guide

🚨 Your $10,000 question, answered

Put your money to work → PortfolioPilot.com